Medication 11: GDNF Therapy: Targeting Neuroprotection and Regeneration
Glial cell line-derived neurotrophic factor (GDNF) therapy is an investigational treatment that aims to protect and regenerate dopamine-producing neurons in Parkinson’s disease patients. By promoting the growth, survival, and maintenance of these neurons, GDNF therapy has the potential to slow disease progression and improve overall motor function.
Currently, GDNF therapy is being investigated through several approaches, including gene therapy, viral vector delivery, and intracerebroventricular infusion. Although clinical trials have shown mixed results, ongoing research aims to refine the methods of GDNF delivery and optimize its therapeutic potential.
As a neuroprotective and regenerative therapy, GDNF could potentially address some of the limitations of current Parkinson’s disease treatments, which primarily focus on symptom management rather than disease modification. However, further research is needed to determine the safety, efficacy, and long-term outcomes of GDNF therapy in Parkinson’s patients. (11)
